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Identifying the leading health and lifestyle factors for the risk of incident demen-
tia and Alzheimer’s disease has yet to translate to risk reduction. To understand
why, we examined the discrepancies between observational and clinical trial evidence
for seven modifiable risk factors: type 2 diabetes, dyslipidemia, hypertension, estro-
gens, inflammation, omega-3 fatty acids, and hyperhomocysteinemia. Sample hetero-
geneity and paucity of intervention details (dose, timing, formulation) were common
themes. Epidemiological evidence is more mature for some interventions (eg, non-
steroidal anti-inflammatory drugs [NSAIDs]) than others. Trial data are promising for
anti-hypertensives and B vitamin supplementation. Taken together, these risk factors
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highlight a future need for more targeted sample selection in clinical trials, a better
understanding of interventions, and deeper analysis of existing data.
KEYWORDS
anti-hypertensives, anti-inflammatories, blood pressure, cholesterol, dementia, diabetesmellitus,
homocysteine, hormone therapy, hypertension, inflammation, omega-3 fatty acids
1 INTRODUCTION
The last 20 years have seen a substantial growth in research on risk
factors for cognitive decline and dementia.1,2 In 2013, this led to an
international petition to theG8Dementia Summit asking governments
to promote research into modifiable risk factors and the prevention of
dementia.3 In the evidence base, multiple longitudinal cohort andmed-
ical record studies have examined dementia risk factors and have been
combined into systematic reviews and meta-analyses,1,2 and the field
is now starting to see reviews of reviews.4,5 However, recent atten-
tion has also focused on a critical examination of gaps in the current
evidence base.6 A key aspect of the latter is the contrast between the
epidemiological evidence and the data from clinical trials, where inter-
ventional trial results for dementia outcomes typically fail to reflect
those of observational risk factor epidemiology. Despite the consen-
sus regarding themain risk factors for dementia, this contrastwith trial
results leaves the evidence in support of risk reduction still compara-
tively lacking, as demonstrated in evidence summaries used to inform
the recentWorld Health Organization (WHO) dementia risk reduction
guidelines.7
Here, we discuss and explore possible explanations for the diver-
gence in findings between the risk factor epidemiology and the risk
reduction trials. We draw on expertise from the Alzheimer’s Associa-
tion International Society to Advance Alzheimer’s Research and Treat-
ment (ISTAART) Professional Interest Area (PIA) on Clinical Trials and
Methodology and leading international experts to appraise and syn-
thesize the evidence, highlight the areas of discrepancy, and propose
the needed next steps. We have selected seven exemplar core risk
factors associated with altered dementia risk. For each of these, a
plausible mechanism exists for the association between the risk fac-
tor and cognition. Even so, trial evidence for risk reduction remains
incomplete. To reduce the potential for bias in the trial evidence,
the selected risk factors are those that lend themselves to blinded
pharmacological intervention. These include the following risk factors
for which pharmaceutical agents are already in use: type 2 diabetes
and antidiabetic medications; dyslipidemias and statins; blood pres-
sureandanti-hypertensiveagents; inflammationandnonsteroidal anti-
inflammatory drugs (NSAIDs); and estrogen and hormone replacement
therapy (HRT). Alongside this, we also examine two nutritional risk fac-
tors and nutritional interventions: omega-3 fatty acids and their sup-
plementation and hyperhomocysteinemia and B vitamins. The review
and commentary is divided into seven separate sections, each consid-
ering one of these risk factors, with each section drafted and shaped
separately by experts in the related field. Each section summarizes the
rationale, the potential biologicalmechanisms, the epidemiological evi-
dence for the risk factor, and the clinical trial evidence for risk reduc-
tion, and provides recommendations for future observational and clin-
ical trial work.
2 TYPE 2 DIABETES MELLITUS
2.1 Diabetes and dementia: An introduction
Type 2 diabetes mellitus (T2DM) is a common chronic disorder
characterized by hyperglycemia, insulin secretion deficiency, and
insulin resistance. T2DM has a global prevalence of ≈9%, and this
is expected to increase with a younger age at onset, particularly in
low- to middle-income countries.8 It is associated with increased
mortality and co-morbidity due to microvascular (ie, retinopathy,
neuropathy, nephropathy) and macrovascular (ie, cardiovascular and
cerebrovascular disease) complications.9 The causes of T2DMaremul-
tifactorial and include a complex interplay of genetics10 and lifestyle
factors, including obesity, a sedentary lifestyle, and energy-dense but
nutrient-poor diets.11
2.2 Potential mechanisms
The pathophysiological mechanisms underlying the link between
T2DManddementia areunclear.12 Someplausiblemechanisms include
(1) vascular pathways from co-morbidities and complications of T2DM
(eg, hypertension and cerebrovascular disease13); (2) cerebral insulin
resistance pathways contributing to neurodegeneration and disrup-
tion of cerebral proteins12–14 (this discovery even led to suggestions
that Alzheimer’s disease (AD) be considered as “Type III diabetes’’14);
and (3) pathways through which hyperglycemia may accelerate amy-
loid plaque aggregation and tau neurofibrillary tangle formation via
accelerated formation of advanced glycation end products.15
2.3 Epidemiological evidence that T2DM is a risk
factor for dementia
Longitudinal epidemiological studies have consistently demonstrated
associations between T2DM and its associated features of hyper-
glycemia and insulin resistance, with risk of cognitive impairment
and dementia.16–20 For example, a meta-analysis of 28 prospective
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observational studies demonstrated that, compared to those without
T2DM, persons with T2DM had a 73% increase in risk of all-cause
dementia, 56% increased risk of AD, and 127% increase of vascular
dementia.19 Caution must be applied, however, since the confound-
ing that is a major challenge to inferring causality from epidemio-
logical evidence is particularly pertinent in a complex disorder like
T2DM that has many contributing factors, co-morbidities, and com-
plications. For example, most studies investigating the link between
T2DM and dementia do not adjust for common cause factors such as
pre-morbid intelligence quotient (IQ), education, and socioeconomic
position, which are the biggest predictors of cognitive function and
impairment later in life, and strong predictors of T2DM.21,22 Informa-
tion on the mediating effects of complications and co-morbidities (eg,
hypertension) are also often lacking. In addition, these studies have
relied on clinical rather than neuropathological diagnoses of AD and
so are limited by misclassification of the outcome.23 When T2DM has
been examined as a risk factor for Alzheimer’s pathology, no associa-
tion is observed; T2DM is associated with cerebrovascular pathology,
however.24,25
A further consideration is to what extent participants in epidemio-
logical studies may have untreated, or undiagnosed, T2DM, especially
given the socially patterned andhealth care–dependent nature of diag-
noses and treatment.
It would be useful for studies to incorporate more objective mea-
sures of the underlying T2DM disease, such as hemoglobin A1c
(HbA1c) level and insulin resistance, which would help elucidate
more mechanistic processes. Although epidemiological studies have
attempted to link these T2DM processes with dementia and cog-
nition outcomes,26 we need more evidence from studies with large
sample sizes assessing the association between T2DM disease pro-
cesses with the whole spectrum of dementia, including the impact
on cognitive function and the level and progression of neuropathol-
ogy associated with dementia, prior to overt clinical expression.27–29
This would help strengthen or weaken our evidence base for a
causal association between the disease processes of T2DM and
dementia.
Self-reported, or linkage with, medication records would also be
beneficial, and there have been efforts to use T2DM medication data
as amain exposure in epidemiological studies,30 but these have yielded
inconsistent results. Careful consideration of timings of treatment,
duration of treatment, and compliance with treatment would help to
elucidate some of these issues.
Mendelian randomization studies use genetic predictors of T2DM
as potential causal instruments to assess causality in settings where
confounders are known to be unmeasured. To date, studies have
reported null associations between the genetic risk of T2DM, glucose
and insulin resistance, and all-cause dementia and AD,31–34 perhaps
indicating that there is not a causal relationship between T2DM and
later-life dementia per se, but implicating other pathways related to
T2DM.22,24 Other causal inference methods are increasingly becom-
ing applicable for clinical medicine and observational studies,35 but as
of yet have not been applied to investigate the association between
T2DMand dementia.
RESEARCH INCONTEXT
1. Systematic review: The authors have reviewed and criti-
cally appraised the current evidence for pharmacological
risk modification and dementia risk reduction for seven
leading modifiable dementia risk factors (type 2 dia-
betes, dyslipidemia, hypertension, estrogens, inflamma-
tion, omega-3 fatty acids, and hyperhomocysteinemia).
2. Interpretation: Critical appraisal of the evidence base
uncovered overlapping themes and knowledge gaps com-
mon to multiple risk factors. Sample heterogeneity and
paucity of intervention details (dose, timing, formulation)
were common.
3. Future directions: There remains a potential for dementia
risk modification, particularly for anti-hypertensive use
and vitamin B supplementation. Further work is needed
to fully establish this: evaluating impact and reducing
bias. Targeted and methodologically sophisticated inves-
tigations are now urgently needed to drive forward
our understanding in this area and to inform recom-
mended targets for concrete and effective risk reduction
strategies.
Future studies should endeavor to measure confounding and medi-
ating influences and may consider applying causal inference methods
alongside more traditional methods to infer more accurate causal esti-
mates of the impact of T2DM on cognitive impairment and dementia
risk.
2.4 Diabetes-related therapeutics: Dementia
reduction trials
Randomized controlled trial (RCT) results to date do not suggest that
anti-diabetic agents as used to treat diabetes are associated with bet-
ter cognitive outcomes. 36 Efforts to summarize the effects of anti-
diabetic agents on cognitive impairment include a Cochrane review of
seven RCTs up to 201736 that found no evidence to favor T2DM treat-
ment to prevent cognitive impairment or dementia. Indeed, there have
even been indications that anti-diabetic agents seem to increase the
risk of cognitive impairment, potentially via hypoglycemic episodes.36
Although therewere initial indications of a potentially beneficial effect
on the incidence of dementia with pioglitazone,37 a thiazolidinedione
insulin sensitizer thought to have a role in microglia regulation, two
phase III trials in patients with mild cognitive impairment (MCI) (Clin-
icalTrials.gov identifier: NCT01931566 and NCT02284906) were ter-
minated early because of a lack of efficacy on primary outcomes,
namely, a change in composite cognitive score over 24 months com-
pared to placebo. Overall evidence from trials to date is deemed
low quality due to the risk of bias in the studies and imprecision
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of the results, for example, the lack of data on blinded assessment
of outcomes, inconsistencies with the primary outcome measures,
patient selection and exclusion criteria, low event rates, and wide
confidence intervals.36 Furthermore, RCTs of anti-diabetic medica-
tion as an intervention for dementia were usually in populations
with MCI, mild dementia cases, 38 or those genetically at risk for
dementia,27,29,39–41 and mostly exclude participants with a diagnosis
or treatment of T2DM, and in some cases, exclude based on glucose
level thresholds.42 There are very limited studies that have included
at least some participants with diabetes,43,44 which in turn enables a
different research question to be addressed: whether there are ben-
eficial effects of AD disease progression in diabetic patients with AD.
In these cases, the placebo group often continues their existing treat-
ment for T2DM, apart from the anti-diabetic agent of interest in the
trial. This is a significant challenge, and more evidence is needed from
larger studies enrolling patients with and without T2DM, with a com-
prehensive history and a range of treatments to enable subgroup
analyses.
We also recommend that epidemiological and RCT studies make it
clearer in their documentation whether participants with T2DMwere
excluded, and if so, how this is defined, given that this information is
often not easily accessible.
2.5 Methodological differences between
observational studies and trials, discussion, and
recommendations for future work
Epidemiological studies and RCTs have heterogeneity and method-
ological variations that make them difficult to compare. The two
approaches often differ in diagnostic criteria and duration of T2DM;
treatment, duration, and dosage of anti-diabetic agents; follow-up
times; populations under investigation; and cognitive outcomes,19 with
trials having been limited in their attempts to reproduce real-life expo-
sures and outcome effects.
Recommendations detailing the potential for alleviating such limita-
tions in future work in T2DMand cognition include:
(i) Where randomization in trials offer gains in precision of controlled
exposure and removal of confounding, RCTs do not mimic real-life
exposures. For example, many studies do not consider duration of
T2DM, prior management, and anti-diabetic agent(s) of choice, or
consider the underlying metabolic effect of treatment, such as the
level of glycemic control, hyperinsulinemia, and insulin resistance
on cognitive impairment.
Our recommendation on measurement of exposure: Given the
dynamic metabolic features of T2DM, complex risk factors, and the
co-morbidities and complications of T2DM, future RCTs and obser-
vational studies should take a life-course phenotyping participants.
This may include measurement of underlying metabolic features and
co-morbidities, duration of T2DM, and medication history, which
will enable suitable matching, monitoring, and the ability to bet-
ter address these potential confounders and mediators in the study
design.
(i) Randomization may weaken the exposure signal because however
precisely isolated it is for the trial, it is likely to occur with complex
co-morbidities in real life.
Our recommendation for treatment: Given that dementia results
primarily from complex progressive disorders, it may be reasonable to
conduct trials with drugs that have actions at multiple targets45 and
multi-modal trials for dementia.46
(i) Existing RCTs in this area lack reliable measures to detect clinically
relevant cognitive change and have frequently been of short dura-
tion when considering the assessment of cognitive change. Most
studies have used theMini-Mental State Examination (MSE), which
is not sensitive to early or subtle changes in cognition over short
time periods and which may be less sensitive to vascular cognitive
impairment.47
Our recommendation on measure of outcome: Future trials should
aim to capture sufficient follow-up to measure clinically relevant
change and to facilitate this using a battery of tests designed to
cover a range of domains of cognitive function, capture individual-level
changes in cognition,48 and differentiate pre-morbid abilities (ie, using
discrepancies between crystallized and fluid functioning, whereby the
former is relatively spared in preclinical AD).49
(i) Epidemiological studies and clinical trials have differing drivers for
sample selection and attrition.
Our recommendation for sample selection and follow-up: Future
studies examining the relationship between diabetes and cognition
should carefully characterize participants to include appropriate at-
risk populations. Studies should also aim to build in mechanisms for
longer-term outcome collection, ideally through longitudinal prospec-
tive data collection that integrates phenotyping of features of T2DM
(hyperglycemia and insulin resistance) across the life course when the
exposure may exert maximal influence and follow-up, even in the face
of shorter-term differential attrition.
3 CHOLESTEROL/STATINS
3.1 Cholesterol, statins, and dementia: An
introduction
Multiple epidemiological studies have shown an association between
reduced dementia risk and statin use, reporting odds ratios of 0.6 to
0.9.50–57 Experimental data using both in vitro and in vivo animal mod-
els of AD suggest pleiomorphic effects of the statins in relation to
the pathogenesis of degenerative disease.58 Such effects include direct
actions on cholesterol lowering, influences on related cardiovascular
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risks including T2DM and hypertension, alterations in inflammatory
pathways, modulation of intracellular trafficking and neurotransmitter
release, aswell as indirect effects on amyloid beta (Aβ)- and tau-related
alterations that are associated with neurodegeneration.58
3.2 The “Statin Paradox”: Introduction and
mechanisms
Statins exert their primary effect by competitively inhibiting 3-
hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the first and
key rate-limiting enzyme of the cholesterol biosynthetic pathway.58
Statins mimic the natural substrate molecule, HMG-CoA, and compete
for binding to the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase
(HMGCR) enzyme. This leads directly to effects on overall circulat-
ing cholesterol levels. The indication for statin use includes reduction
in hypercholesterolemia, which has been linked to increased risk of
cardiovascular and cerebrovascular events. Such consequences can be
directly responsible for the development of cognitive impairment and
dementia; or, more frequently, can be associated with cerebrovascu-
lar disease that interacts additively and possibly even synergistically
with other neurodegenerative pathways.52 Much research has also
suggested that genetic alterations affecting cholesterol trafficking and
modulating pathways are related directly to increased risk of AD, sug-
gesting the potential for other risk reduction pathways.50
3.3 Cholesterol and statins: The epidemiological
evidence
The epidemiological associations between statin use and reduced risk
of dementia have been reviewed in several recent publications includ-
ing anupdate of theCochranedatabase.50,53–57,59,60 These data clearly
demonstrate an association between statin use and a lowered risk for
all-cause dementia, and AD specifically, but notably they provide con-
flicting results for the reduction of dementia caused by cerebrovascu-
lar disease. The influence of aging adds complexity here because much
work in the field is focused on the relationship of midlife rather than
late-life hypercholesterolemia in modulating dementia risk.51 Accord-
ingly, some of the variability seen in epidemiological studies may be
related to the timing and exposure characteristics for the statin ther-
apy identified as possibly modulating risk for future decline in cogni-
tionand in thedevelopmentof dementia. Yet, otherworkhas suggested
that the various statin drugs are not uniform in their effects on degen-
erative disease processes but instead have specific characteristics that
maydiffer. Consequently,when statins are clustered as a uniformexpo-
sure in epidemiological association studies, such exposure may reduce
the opportunity for clarity and may lead to inconsistent results.56,61
Major factors include type of statin, dosage, length of exposure, and
timing in the life-coursewhen exposure occurred. Yet, the data are suf-
ficiently conclusive to warrant clinical trials of statin therapy to reduce
the risk and or delay the progression of cognitive decline and degener-
ative dementia.
F IGURE 1 Confounds that have plagued clinical trials of statin
therapy
3.4 Cholesterol and statins: The clinical trial
evidence for statins and their influence on dementia
risk
Several studies have, therefore, investigated the hypothesis that statin
therapy may be beneficial for the treatment of dementia. However,
despite the promising epidemiological and observational data, results
have been disappointing,56,61 as the trial data appear to contradict the
epidemiological data. Attempts at an explanation for this discrepancy
have focused back on the multiple sources of low precision inherent in
the epidemiological studies, including again the type of statin, dosage,
length of exposure, and timing of exposure in the life-course56,61 (Fig-
ure 1). In addition, many trial design considerations may explain the
discrepancy. These include inclusion and exclusion criteria that restrict
participants in ways that are inconsistent with observational stud-
ies, for example, different population characteristics and selection of
statin, and dose, duration of exposure, and timing in the life-course,
which are again discordant with observational results.22,53,61 We con-
sider each of these considerations in the sections to follow.
Inclusion and exclusion criteria. One critical difference between
the many null-finding statin clinical treatment trials and observa-
tional studies is that persons enrolled in clinical trials were not
recruited based on dysregulated lipid status.53,61 Indeed, some tri-
als excluded from enrollment those participants whose lipid status
revealed dysregulation.53,61 The contrast with clinical use (and resul-
tant observational studies) is obvious. Secondary analyses of the data
from several clinical trials have implicated genetic background, espe-
cially apolipoprotein E gene (APOE) ɛ4 status as a primary modula-
tor of statin effects that may be related to risk of cognitive decline
in dementia.50 Further trials should take such considerations into
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account when designing maximally appropriate inclusion/exclusion
criteria.
Selection of statin: Clinical trials of statins for cognitive outcomes
have focused largely on atorvastatin and pravastatin. Although other,
smaller trials includedother statins,meta-analytic studiesof thepoten-
tial beneficial effect of statin therapy have typically considered statins
as a single group. Yet, clinical experience suggests that the statins are
quite diverse in their effects on high-density lipoprotein (HDL) as well
as low-density lipoprotein (LDL) modulation. Common practice dic-
tates that if a patient fails one statin, another agent should be tried.
Such flexibility in selection of agents has not yet been incorporated
into clinical trial methodology. Thus many who are intolerant of the
assigned statin in a trial might have benefited from an alternate drug.
Statin dose: The dosage of statins in clinical trials for the prevention
of cognitive decline and dementia have typically been in the mid-range
based on studies of systemic cholesterol modification, without the
inclusion of adaptive trial design to enable maximum dose for unique
participants. This issue relates partially to theusual inclusion andexclu-
sion criteria for such trials, which, unlike in clinical use, do not consider
the type or severity of dyslipidemia when selecting a statin agent or
dose.53,61 At least with respect to dose, consideration of an adaptive
design protocol might allow flexibility in optimizing dose, based on sys-
temic pharmacodynamic profiles, for prevention of cognitive decline.
To date, a central nervous system (CNS)–specific pharmacodynamic
profile that might guide optimal statin dosing for dementia prevention
has not been established.
Durationof exposure: Themajority of clinical trials testing statin use
for the prevention of dementia or cognitive decline have had relatively
short durations, typically about 2 years.53,61 By contrast, the observa-
tional data on cognitive consequences of statin use for modulation of
cardiovascular risks suggests that a much longer duration of exposure
may be necessary for the desired effect on cognition.54,56 Prolonged
trials of statin therapy should therefore be considered when designing
new trials of statins for the prevention of cognitive deficits.
Timing of exposure across the life-course: As noted above, a criti-
cal issue with the discrepancy between observational and clinical trial
data regarding the potential benefits of statin therapy in preventing
cognitive decline may be the timing of exposure across the life-course.
Observational studies often include exposure at any point in the life-
course, especially in midlife or early old age.54,56 By contrast, most
statin trials to date have enrolled persons at older age and several with
some level of existing cognitive impairment, when, arguably, a great
deal of neural damage is already evident.53,61,62 Although it would be
prohibitively costly to conduct a clinical trial that tests later-life cogni-
tive consequences of midlife exposures, there may be ways to achieve
the same aims, using new technologies to detect early changes of neu-
rocognitive disorders or ancillary cognitive studies of midlife trials and
looking at the late-life conversion to dementia; such studies may ulti-
mately provide the answers as towhether statin therapy can intervene
in the development of late-life cognitive decline and dementia.
3.5 Statins and cognition: Conclusions and
recommendations for future work
Although the number of prospective, randomized, placebo-controlled
clinical trials that have failed to provide evidence for the benefit
of statin therapy in reducing the incidence of cognitive decline in
dementia argue strongly against further investigations in this area, the
data supporting the use of such therapy from observational studies
is overwhelmingly supportive of further investigations.50,51,53–61,63,64
The field is now poised to look back and reconsider essential clin-
ical trial flaws in the design and conduct of such research in an
attempt to improve on the critical confounds of inclusion and exclu-
sion criteria for the participants, selection of statin, statin dose, dura-
tion of exposure, and timing in the life-course when the exposure
should maximally exert its influence.56,61 Understanding the discrep-
ancies between observational and clinical trial data regarding the
use of statins for the prevention of cognitive decline in demen-
tia is critical to uncovering whether the observational data repre-
sents pure epi-phenomena that is unrelated to the underlying disease
course.
Recommendations for future clinical trials of statin therapy
include:
1. Selection of an appropriate population including those with choles-
terol/lipid dysregulation
2. Adaptive design in the selection and dose of statin
therapy
3. Enhanced duration of exposure with consideration of timing within
the degenerative cascade when therapy may prove most bene-
ficial. Creative approaches such as ancillary cognitive studies of
midlife trials, looking at the late-life conversion to dementia are
warranted.
4 BLOOD PRESSURE AND
ANTI-HYPERTENSIVES
4.1 Blood pressure and anti-hypertensives: An
introduction
Epidemiological evidence has consistently shown a relationship
between higher blood pressure (BP) and an increased risk of develop-
ing cognitive decline and dementia.65 Several plausible mechanisms
support the potential for raised BP driving impairment in brain struc-
ture and function.66 BP reduction is possible via several established
classes of anti-hypertensive medication that are widely available and
present in treatment pathways for cardiovascular risk reduction.67
However, relatively few trials of anti-hypertensive drugs have mea-
sured cognitive outcomes or incident dementia, and those that have,
have been largely inconclusive.
PETERS ET AL. 7 of 23
4.2 Potential mechanisms linking raised blood
pressure to impaired cognition
Mechanisms by which raised BP may lead to impaired cognitive func-
tion and dementia have been summarized elsewhere.66,68 They include
damage to the vascular structure (eg, increased risk of clinical and
subclinical stroke, promotion of atherosclerosis, vascular remodeling
and stiffening reducing effective perfusion, small vessel disease lead-
ing to white matter lesions and microvascular rarefaction leading to
loss of microvessels), and to function (eg, disruption of endothelial cell
function leading to impairedmicrovascular flow, disruption of the neu-
rovascular coupling attenuating the ability for cerebral blood flow to
respond to neural activity, impaired autoregulation, and loss of blood-
brain barrier integrity).66,68,69 There is also evidence to suggest that
high BP and vascular risk may be associated with deposition of Aβ.
66,70–72
4.3 Epidemiology of blood pressure and cognition
Alongside the plausible mechanisms there are a large number of epi-
demiological studies linking raised BP to incident cognitive decline or
dementia.73,74 This is particularly the case for raised BP in midlife,
implying a role for aging similar to the evidence for raised choles-
terol. A 2005 review highlights 11 of 13 studies reporting a relation-
ship between higher BP and incident cognitive decline or dementia in
populations 40s to 50s and followed for ≈20 years.65 In contrast, for
populations in their 60s and 70s, although high BP remains a risk fac-
tor the evidence is more mixed. The same 2005 review found only 6
of 21 studies reporting higher pressures in later life associated with
increased risk and a further 3 studies reporting a U-shaped relation-
ship,with both lowandhighpressures associatedwith increased risk.65
More recentwork supports the need for a life-course perspective high-
lighting characteristics particularly relevant to BP75,76 : for example,
chronicity, the change in diastolic and systolic pressure with aging and
the steeper rise and subsequent fall in pressure observed 2 to 5 years
before dementia diagnosis and the potential for differential mortality
in higher and lower BP populations. It is in the context of this epidemi-
ology that wemust examine evidence from the trials.
4.4 Anti-hypertensives: Randomized controlled
trials and dementia
Several randomized controlled and blinded trials of anti-hypertensives
have assessed cognition or dementia outcomes. However, their results
have been largely inconclusive.77,78 In general, cognition and incident
dementia have been secondary end points, or assessed in ancillary
studies, in trials designed primarily to examine the cardiovascular ben-
efits of antihypertensive use in later-life populations. This point has
driven threemain issueswhenconsidering evidence for thepotential of
anti-hypertensives to reduce the risk of cognitive decline and demen-
tia: (1) the lengthof follow-up, (2) the selectionof anappropriately aged
population, and (3) the assessment of cognitive function and cognitive
decline.
(1) The primary focus on cardiovascular outcomes has typically
resulted in relatively short follow-up for cognition, and some trials
have even been stopped early following observed cardiovascular ben-
efit. The early stopping and lack of long follow-up (most are less than
the recommended minimum of 5 years)78,79 has very likely exacer-
bated a lack of statistical power to detect cognitive and dementia
outcomes, as these develop more gradually over time. For example,
mean follow-up in anti-hypertensive trials that havemeasured demen-
tia (double-blind randomized phase rather than longer term open-label
follow-up) ranges from 2.0 to 4.3 years.77 (2) A common focus of anti-
hypertensive trials for elderly individualsmay alsomean that the inter-
vention ignores the most relevant, younger (midlife, or earlier adult
life) target population for cognition and anti-hypertensive use. The trial
populations have, by design, been drawn from people in early late life
or older.Most of the trials recruited populations entirely from later life
(≥60 years), and even the trials open to including people in their 50s
arrived at mean baseline ages in the mid-60s. Trials that report on cog-
nitive outcomes show similar issues.78 (3) Most of the trials have also
used a relatively insensitive cognitive screening instrument as the pri-
mary cognitive assessment tool. This limits their ability to detect more
subtle cognitive change.78
Trials in this area have also been constrained by the development
of the cardiovascular evidence base. That is, as the cardiovascular evi-
dence base has grown, the drug-prescribing guidelines and thresholds
for treatment have changed. Guideline changes to recommend treat-
ment in a new population drives consequent ethical requirements to
treat, thus shaping the populations that can be selected for each subse-
quent trial, or having limiting effects on recruitment due to accommo-
dating aspects around prior exposures.80 This has driven each new trial
to recruit to different baselineBPs, ages, or cardiovascular risk profiles,
thereby furthering the heterogeneity across the evidence base.
Despite these limitations, there is a growing evidence base
for anti-hypertensive treatment as having a role in dementia risk
reduction,81,82 Meta-analyses, particularly those that focus on double-
blind trials, generally find point estimates (odds ratio, relative risk,
hazard ratio) of around 0.9 in favor of anti-hypertensive treatment
reducing risk of dementia 83,84 and showing a potential for dose-
response.77,83,85 For example, trials that achieved greater than a
10 mm Hg reduction in BP between their two randomized arms had a
combined 12% (95% confidence interval [CI] 22%-2%) risk reduction
for incident dementia compared to a nonsignificant result (relative risk
0.98 (95%CI 0.88-1.09) in those who did not achieve this difference.77
Questions remain as to the ideal range of BP for brain health, which
may be specific to different levels of chronological, or more likely bio-
logical, age and prior BP exposure. Furthermore, recent and potentially
paradoxical results from the Systolic Blood Pressure Intervention Trial
(SPRINT-MIND)85,86 have highlighted the possibility of increased cog-
nitive risk from lowering BP too far86 and served to once again high-
light the complexities and knowledge gaps in this area.
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4.5 Blood pressure and anti-hypertensives:
Summary and recommendations
In summary, although overall the direction of the epidemiology and
clinical trial evidence is broadly congruent, and more congruent than
some of the other risk factors, this is still insufficient to tell us whether
reducing BP for dementia risk reduction is effective.
Recommendations for future work on anti-hypertensives, blood
pressure, and cognition include:
1. New sophisticated analysis of the existing epidemiology and clin-
ical trial data, for example, using causal inference methods and
more appropriately taking account of competing risks alongside
using more sophisticated modeling to examine the role of different
achieved BP levels and attrition.
2. New data collection is needed to evaluate relevant populations.
In particular we need a clear understanding of the relationship
between BP and cognition over the life-course, and at ages 20,
30, or 40 years prior to dementia onset, for example, by collect-
ing longer-term prospective or even retrospective data on both BP,
cognition, and anti-hypertensives.
3. Related to point 2 above, we also need a better understanding of
the role of trajectories of change in BP and any consequent change
in ideal BP ranges (alongside changes in other dementia-influencing
factors).
4. We need to start using sufficiently sensitive cognitive outcome
measures.
5 ESTROGEN AND HORMONE THERAPY (HT)
5.1 Hormones and HT: Introduction and potential
mechanisms
Estrogen and supplementation using oral hormone therapy (HT) have
been proposed as a treatment for observed changes in memory and
dementia risk in women who are experiencing menopause. There are
several plausible biological mechanisms for cognitive benefits from
estrogen supplementation after menopause.87,88 Estrogen receptors
are widespread in the brain and regulate synaptogenesis,89 particu-
larly in the hippocampus.90 For example, rats show reduced density of
dendritic spines after oophorectomy.91 Estrogen also interacts with or
modulates neurotransmitters that are important for cognition such as
dopamine and serotonin.89,92 Animal studies have also provided evi-
dence for a “sensitive period” during which the therapeutic benefit
of estrogen supplementation may occur, and suggest that estrogen-
mediated cognitive benefits may be lost if treatment is commenced
before, or after, a specific age.93
5.2 HT and cognition: Epidemiology
Systematic reviews of the epidemiological data have consistently
shown that HT is associated with reduced risk of late-life dementia.4
Most cohort studies that report on HT in relation to dementia out-
comes make comparisons between women who have “ever” used HT
with those who have “never” used HRT.94 Data are lacking on estrogen
creams and the use of HT for short periods, for example, for less than 6
months.94
Positive early observational findings95–97 ranged from a 39% to
50% effect size for the reduction in AD risk associated with HT use.
Comparable evidence was demonstrated in one review, which showed
that the strongest evidence for HT in AD risk reduction came from
2 cohort studies and 10 case-control studies, which showed a pooled
34% decrease in AD risk (95% CI 18%-47%).89,98 An additional review
found the pooled risk ratio of cohort studies using HT in AD preven-
tion to be a 39% reduction [95% CI 24%-54%]1. More recent obser-
vational evidence has also suggested a benefit of HT on cognition in
postmenopausal women, with longer duration associated with greater
benefit in the population-based Cache-County cohort study.97,99 The
12-year follow-up of the Cache-County study found a significant “sen-
sitive period” effect, with timing of HT commencement being signifi-
cantly related to cognition (assessed using the extended mini-mental
state exam, the 3MS) such that those commencing within 5 years of
menopause performed better than those commencing HT 6 or more
years following menopause, with greater benefit conferred to older
women.99
Early observational data were subject to significant confounding,
with depression typically not controlled, and thewomenwhowere pre-
scribed HT being more educated, in better overall health prior to HT
commencement, and leading healthier lifestyles than women not given
HT.100,101 LeBlanc et al. also note potential bias by contraindication
in observational studies whereby women who already have dementia
are less likely to receive HT due to issues relating to compliance and
interactive effects between the HTs and existing medications.98 Error
may also be introduced in reporting, with many studies using proxy
reports, which could lead to bias due to the proxy being unaware of
any previous HT use. A limitation of the meta-analyses of the obser-
vational data is the lack of consistency in the information on age of
exposure.4 When measures are taken several years apart in panel sur-
veys the exact timing ofHT in relation tomenopausemay not be clearly
specified.
5.3 HT and cognition: Clinical trial evidence
A systematic review of the clinical trial evidence for the effect of HT
on cognitive outcomes did not find benefit.102 The Women’s Health
Initiative Memory Study (WHIMS), a double-blind, placebo-controlled
clinical trial examining 8300 women 65 years of age or older over a 2-
year period to observe the effects of HRTs and dementia progression.
The trial failed to find a beneficial effect for HT in reducing demen-
tia risk, instead finding an increase in all types of dementia.103,104 One
explanation for the discrepancy between WHIMS and early observa-
tional findings is the differences in timing of treatment onset.Whereas
observational studies followed women who had commenced HT dur-
ing menopause, in WHIMS, participants were randomly allocated long
into the post-menopausal phase.94 The “sensitive period hypothesis”
suggests both the observational andWHIMS findingsmay be accurate,
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with differences in effects being accounted for by the timing of treat-
ment onset, rather thanmethodological concerns.94
When examining variation in the timing of treatment initiation, one
review of RCTs found little support for the effects of HT on cognition
in older women (65 years and older), although it cited potential bene-
fits to younger women (younger than 65 years) for HT across certain
cognitive domains. The author found that this was especially true for
womenwhohad symptomaticmenopause andwhoweremore recently
menopausal.105 Despite this, the author noted that although larger
RCT data for older women with late-life HT exist, there is a dearth
of larger RCTs that examine HT in younger women. One review of 22
double-blinded RCTs found that only 30% of women were 50 to 59
years old during baseline, the age at which women are mostly likely
considered for HT to alleviate symptoms102 and most likely relevant
to the sensitive period hypothesis.
LeBlanc and colleagues98,106 reviewed RCTs on HT and cognition
and found significant heterogeneity in the cognitive tests employed
across HT RCTs. Across nine RCTs, more than 40 different tests were
utilized, and within the consistently used tests only 7 of 40 were used
across more than one study and with varied administration. Regard-
ing treatment, RCTs were inconsistent in the duration of administra-
tion, specific dosage, and formulation used (only two studies used the
same formulation and dose).98 The authors concluded that there is cur-
rently insufficient data regarding the attenuating effects of varied for-
mulations and dosages on cognition. These studies also tended to be of
poorer quality (only one out of 10 rated as “good”). Other authors sug-
gest that effect sizes of RCT findings are often limited by a large age
range107 and inclusion of participants with early- and late-onset AD
at baseline.100,107 Despite the above it is also important to note that
given the evidence for longer duration of HT use being associated with
increased risk of cardiovascular disease, breast cancer, and stroke, HT
is not currently recommended for treatment in the prevention of cog-
nitive decline or dementia.102,108
5.4 Hormones and HT: Summary and
recommendations
In summary, despite the biological plausibility for estrogen being neu-
roprotective, and some positive findings from observational studies,
the potential of HT to reduce the risk of cognitive decline and demen-
tia is not found in RCTs to date. There are several important gaps in this
literature.
Recommendations for future studies in HT and cognition include:
1. The effects of long-term HT use in perimenopausal women, and
postmenopausal women ages 50 and younger on cognition should
be evaluated.
2. The potential role for HT type should be considered in relation to
risk of dementia with other women’s health variables such as hys-
terectomy and oophorectomy also included for consideration.
3. Data are needed on the association between HT and Vascular
Dementia (VaD) or other non-AD dementias in the observational
literature.4
4. There is a greater need for evidence for more globally diverse
data for HT in order to understand effects not only across
the life-course, but across sociodemographic, racial, and cultural
backgrounds.4
6 INFLAMMATION AND NSAIDS
6.1 Inflammation and NSAIDs: An introduction
In 1988, Joseph Rogers and Patrick McGeer reported the presence
of Human Leukocyte Antigen – DR isotype (HLA-DR) and other T-
immune cellmarkers around neuritic plaques in ADbrains.109,110 Sens-
ing that such immune activitywas probably contributory (not adaptive)
to AD pathology, McGeer studied the relationship between rheuma-
toid arthritis (RA; almost always treatedwith anti-inflammatory drugs)
and AD.111 AD appeared to be rare in patients with RA, and vice
versa. Among four explanations for this finding, McGeer consid-
ered the possibility that “AD (does) indeed develop less often in the
RA population, but this is unrelated to anti-inflammatory drugs.”111
Alternatively stated, he noted the possibility of confounding by
indication.
6.2 NSAIDS: Further observational data
Two years later, a co-twin control study investigated a broad agnos-
tic array of antecedent exposures in 50 AD-discordant twin pairs. This
search revealed only that a history of arthritic conditions or anti-
inflammatory treatmentswas inversely associatedwith theoccurrence
of AD.112 The study’s authors then investigated NSAID use versus AD
in a sample of siblings from families with a multiplex history of AD
dementia,113 finding an inverse association between a report of sus-
tainedNSAIDuseand theonset ofAD.These analyses consideredahis-
torical report of “arthritis” (not otherwise specified), which appeared
not to modify onset except in those treated with NSAIDs. In the ensu-
ing years, numerous epidemiological studies—some including attempts
to control for confoundingby indicationand inclusionof a control expo-
sure (acetaminophen / paracetamol)—suggested a benefit of sustained
NSAID use. This trend reached its zenith with publication in the New
England Journal of Medicine of findings from the Rotterdam Study.114
The Rotterdam cohort was relatively youthful for an investigation of
dementia (median age at entry of mid- to late-60s). Relying on a pre-
scription registry, it suggested a time-dependent inverse association
betweenADandNSAIDs, culminating in an 80% reduction in incidence
for persons with≥5 years of continuous NSAID use.
6.3 Contrast with randomized controlled trials of
NSAIDS
The following years witnessed a series of carefully conducted RCTs
that failed to affirm the observational findings. The Alzheimer’s
Disease Cooperative Study (ADCS) reported clinical trials of
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prednisone (a powerful immunosuppressant), and, a few years later,
two NSAIDs (naproxen and rofecoxib). Both failed to show benefit in
ADpatients.115,116 A trial of the anti-malarial drughydroxychloroquine
(which also has substantial immunosuppressant activity) showed no
benefit.117 AnRCTof rofecoxib (a selective cyclo-oxygenase 2 [COX-2]
inhibiting NSAIDs) failed to suggest that drug’s ability to postpone
“conversion” of MCI to AD dementia.118 Here, the hazard ratio (HR)
for conversion to AD with assignment to rofecoxib was a worrisome
1.46 (95% CI 1.09-1.94). Shortly thereafter, the ADAPT research
group reported similarly adverse findings in 25 incident cases, relating
the risk of incident AD dementia to the treatment of asymptomatic
elderly (age ≥70 years) with the COX-2 inhibitor celecoxib (HR 4.11,
95% CI 1.30-13.0) or naproxen sodium (HR 3.57, 95% CI 1.09-11.7)
versus placebo.119 Because ADAPT was stopped early, its incident
AD cases became evident after no more than 3 years of treatment,
suggesting that these persons had advanced pre-symptomatic disease
when treatments were initiated. The latter conjecture was supported
to some degree in the 3-year ADAPT Follow-up Study, which showed
dissipation of the adverse associations, 120 and by a detailed analysis
of the original ADAPT data suggesting that naproxen treatment accel-
erated cognitive decline among the one-third of participants showing
the greatest rate of decline.121
These findings seemed to suggest that the ideal population for
NSAID treatment would be at-risk “young-elderly” persons without
inflammatory disease. Participants should then be further removed
from their possible age at onset of AD dementia. But the difficulty for
such trials lay in measurement of the progression of pre-symptomatic
AD. Only with such measurement could one expect to see that NSAID
treatments would retard this progression. Attempting to address this
problem, Canadian investigators assembled a younger (median age
63 years) asymptomatic cohort for PResymptomatic EValuation of
Experimental or Novel Treatments for AD (PREVENT-AD cohort).122
Their risk of AD was likely increased by a requirement that each had
a parental or multiple-sibling history of AD dementia. They were eval-
uated annually using the 45-minute Repeatable Battery for Assess-
ment of Neuropsychological Status, 123 and a broad array of other
evaluative procedures, as detailed in reference122 and a companion
paper that describes the development of a composite indicator of
pre-symptomatic AD progression, the “Alzheimer Progression Score”
(APS).121
Some 200 members of the PREVENT-AD cohort were enrolled
in INTREPAD, a 2-year placebo-controlled RCT of naproxen sodium
220 mg, b.i.d.124 The INTREPAD primary outcome was the APS—after
validation efforts in the remaining ≈175 PREVENT-AD participants
had shown its excellent longitudinal stability and portability to the
trial sample. Slightly more than half of INTREPAD participants also
donated annual cerebrospinal fluid (CSF) samples for immune marker
studies.125 The trial results indicated (1) a significant increase in par-
ticipants’ APS over the 2-year trial interval, but (2) no suggestion of
anymitigation in this change among naproxen-assigned individuals. No
single component of the APS showed any suggestion of benefit from
naproxen.
6.4 Later observational studies affirm the trial
results and suggest adverse consequences of NSAID
use among very elderly persons
Perhaps resolving the discord between trial and observational study
results, more recent observational data appear mostly to side with
the available trial results. Since 2000, numerous investigations have
shownnull orworse association betweenNSAIDexposure andAD inci-
dence. A consistent feature of these later studies was their reliance on
populations considerably older than the Rotterdam cohort. Thus the
elderly (age at entry 65-106 years) population-based MoViES cohort
study found no association of NSAID use with occurrence of AD (data
described in126). Similar results were observed in the Religious Orders
Study – Memory and Aging Project (mean age at entry = 75 years
with mean follow-up of 12 years).127 Perhaps most surprising, results
from the population-based Adult Changes in Thought observational
study suggested a strong apparent increase in AD incidence among
“heavy” users of NSAIDs (data from computerized prescription reg-
istry; hazard ratio 1.66 with 95% CI 1.24-2.24).128 These persons had
consumed≥500 defined daily doses of NSAIDs over two ormore years
butwere again quite elderly, with amedian age at entry of 75 years and
follow-up typically of a decadeormore.Given thewell-knownepidemi-
ologic relation of age to AD incidence (eg, >20% cumulative incidence
by age 80), and recent awareness that AD pathological changes begin a
decadeormoreprior to symptoms, cohorts in their late70s andbeyond
would likely include>30% of participants with demonstrable evidence
of (pre-symptomatic) AD pathology.129,130 In sum, the singlemost con-
sistent findingof theobservational data onNSAIDs appears tobe a lack
of benefit (and even a potential for harm) when persons in later old age
are exposed to NSAIDs.
6.5 Should we attempt further RCTs for AD
prevention using NSAIDs? Summary and
recommendations
The disappointing results from INTREPAD suggest that participants in
any new trial should be even younger, probably younger than 60 years
of age, and perhaps without prominent AD risk factors. The size and
duration required for such a trial would likely render it prohibitively
costly and difficult to execute. If this sort of trial were, nonetheless,
contemplated, its sponsors should probably consider several other
experimental findings:
∙ Should the trial choose adifferentNSAID intervention?Only a select
group of NSAIDs have a capacity to inhibit gamma secretase activ-
ity, which is an important step in the cleavage of the amyloid pre-
cursor protein to Aβ fragments, ostensibly essential (if perhaps not
causal) for early AD pathogenesis.131 Some authors have, therefore,
lamented the fact that none of the completed NSAID RCTs tested
ibuprofen or other “gamma secretase-modulating” (GSM) agents.
But observational data, at least, suggest that GSM activity may
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not be important. A meta-analysis of six key cohort studies whose
17,000 participants had contributed 77,000 person-years of obser-
vation showed the familiar result of reduced dementia incidence
among chronic NSAID users.126 But the data failed to show any dif-
ference in apparent “protection” offered by GSMNSAIDs compared
with others, or in the apparent effects of their most common exem-
plars ibuprofen and naproxen.
∙ Will the chosen intervention cross the blood-brain barrier in suf-
ficient concentration to modify the brain “inflammatory” (innate
immune) changes that accompany AD pathogenesis? Findings
among INTREPAD participants showed that treatment with low-
dose naproxen (the conventional NSAIDmost commonly used in AD
trials) produces appreciable levels in the CSF.125 These levels repre-
sent only about 1% of concentrations found in the plasma of treated
subjects, but this result is not necessarily surprising given that about
99% of naproxen in plasma appears to be protein-bound (and there-
fore of doubtful effect).
∙ Will the chosen agent have appreciable effects on important
immune and inflammatory markers in CSF (therefore, probably in
brain)? Another finding from the study of INTREPAD CSF was that
assignment to naproxen resulted in little or no consistent change in
levels of important immunemarkers indicating “inflammatory” brain
changes. Accordingly, there may be significant concern that none of
the NSAID treatment or prevention trials used “anti-inflammatory”
agents that would be likely to affect the changes described by
Rogers, McGeer, et al.109,110
6.6 Concluding thoughts on the disparity
between the NSAID trial and observational results
The earliest published work on this topic considered the possibility
of confounding by indication. None of the described observational
studies was able in multivariate analyses to exclude the possibility
that an apparent benefit with NSAIDs was attributable to confound-
ing by an inflammatory diathesis. In particular, the above-cited meta-
analysis of six cohorts126 considered the possible influence of an
“arthritis” (mostly osteoarthritis) variable. As in several other studies,
this variable appeared to strengthen the inverse NSAID–AD associa-
tion (arthritis sufferers are probably obligatory NSAID users). Notably,
however, the “arthritis” variable itself was associated with diminished
AD incidence, even after “adjusting” for reported NSAID use. If repro-
ducible, this finding suggests little reason to expect trial results to
affirm a benefit of NSAIDs in persons without evidence of inflamma-
tory disease (an exclusion criterion in all the cited trials). We have
therefore come to have strong doubts about the possible benefit
of NSAIDs for AD prevention. Instead, we recently conjectured (as
first discussed in McGeer’s pioneering work) the aforementioned “. . .
results may suggest re-consideration of . . . a pro-inflammatory diathe-
sis (itself) as a possible explanation for the reduced AD incidence
among (relatively young) NSAID users in observational studies,” 124
that is, confounding by indication.
Recommendations:
1. Future work on pharmaceutical interventions for dementia risk
reduction must remain vigilant to potential sources of bias, not the
least those of reverse causality and confounding by indication.
2. Any contemplated new trial of anti-inflammatory interventions for
AD prevention should avoid enrolling very old participants or oth-
ers with evidence of advancing pre-symptomatic AD pathology.
7 OMEGA-3 FATTY ACIDS AND
SUPPLEMENTATION
7.1 Omega-3 and supplementation: An
introduction
Mediterranean,132 Mediterranean-Intervention for Neurodegenera-
tive Delay (MIND),133,134 and prudent 135,136 dietary patterns have
been associated with slower cognitive decline and lower risk for devel-
oping AD. These associations may be attributable to the higher intake
of plant-based foods and seafooddense in unsaturated fatty acids, vita-
mins and minerals, and flavonoids and polyphenolic compounds, and
there is some evidence associating increased seafood consumption,
omega-3 intake, or omega-3 blood levels, with a lower risk of demen-
tia, or of cognitive decline.137 Isolated components from these diets,
including the omega-3 polyunsaturated fatty acids (n-3 PUFAs)138,139
and the homocysteine-lowering B vitamins140–142 (Section 8 in subse-
quent text) have been formally tested in slowing cognitive decline or
AD progression, but the results of randomized clinical trials have been
inconsistent. This section and the following Section 8 provide updates
and insights into n-3 PUFAs and B vitamins, respectively, in the pursuit
of developing more effective nutritional-based interventions for pre-
vention of age-related cognitive impairment and dementia.
n-3 PUFAs have a variety of bioactive properties that regulate phys-
iological functions and there are various potential mechanisms for
the role of n-3 PUFAs in cognition. The two major n-3 PUFAs are
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). DHA is
quantitatively the most abundant n-3 PUFA in human brains, whereas
EPA is present in very limited amounts.143 The small concentration
of EPA in the brain does not necessarily translate into a weak bio-
logical activity. Given that EPA and DHA can inter-convert in vivo,144
it is possible that both or either fatty acid may have similar neuro-
protective effects. Although EPA is reported to have greater anti-
inflammatory effects145 and has been associated with greater white
matter integrity,146 because themajority of preclinical studies to guide
pharmacokinetics (PK) and pharmacodynamics (PD) were conducted
using DHA,147 we focus on DHA in this review. It is important to note
that neither EPA nor DHA can be synthesized de novo but can be
obtained from diet/supplementation.
In contrast to the pre-clinical studies in ADmousemodels that bring
some support for a role for long-term and high-dose omega-3 fatty
acid intake in improvingmeasures of cognition, clinical trials testing the
effect of omega-3 supplementation on cognition have largely been dis-
appointing. We examine the pharmacological properties of omega-3s
in the brain in relation to study designs to understand this discrepancy.
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TABLE 1 Existing DHA formulations
DHAEster Formulation Properties
Triacylglycerol ester DHA esterified to triacylglycerol backbone Most abundant natural form of DHA
Ethyl esters DHA esterified to ethanol Synthetic form that converts into TG or PL
DHA after absorption
Phospholipid esters DHA esterified to phosphatidyl choline or
phosphatidyl serine
Demonstrates greater brain uptake compared
with the other forms
7.2 Omega-3 and cognition: Epidemiology
A possible role for n-3 PUFA consumption was also shown in a meta-
analysis of 21 longitudinal studies (181,580 participants) with 4438
dementia cases reporting that a one-serving per week increment of
dietary fish was associated with lower risks of dementia (RR 0.95,
95% CI 0.90-0.99; P = 0.042, I(2) = 63.4%) and AD (RR 0.93, 95% CI
0.90-0.95; P = .003, I(2) = 74.8%). More specifically, the increment
of dietary DHA intake was associated with lower risks of dementia
(RR 0.86, 95% CI 0.76-0.96; P < .001, I(2) = 92.7%) and AD (RR 0.63
95% CI: 0.51, 0.76; P < .001, I(2) = 94.5%).137 The KORA (KOop-
erativen Gesundheitsforschung in der Region Augsburg)-Age study
has also reported a cross-sectional association between low omega-3
index (<5.7%) and cognitive impairment in an elderly population of 720
participants with cognitive status ranging from cognitively normal to
suspected dementia.148
7.3 Omega-3 and cognition: clinical trials
Overall, the effects of omega-3 supplementation on cognition have
been disappointing in several randomized clinical trials.149 One pos-
sible explanation is the confounding effect observed in observational
studies, where lower omega-3 levels could represent biomarkers of
poor dietary networks150 that affect several factors (other nutrient
levels, lifestyles, or risk factors) and therefore intake or levels of
omega-3 per se may not be causally related to dementia. However,
there is good biological evidence that omega-3 intake has neuropro-
tective effects in AD animal models.151 It is plausible that omega-3
supplementation started after the onset of significant neurodegener-
ation is too late, where the disease process may not be reversed by
omega-3 supplements. There are many challenges for conducting pre-
vention trials including identifying an omega-3 dose that gets to the
brain, the population thatmay benefit from supplementation, the dura-
tion of supplementation, and sensitive cognitive outcomes.
7.3.1 Omega-3 fatty acids: Dose and delivery
Animal studies provide useful information on DHA brain pharmacody-
namics with AD biomarkers as readouts (amyloid, tau, synaptic func-
tions, andmakers of neurodegeneration). In a systematic review, Hooi-
jmans et al. 151 reported cognitive and AD biomarker benefit using
doses of DHA supplementation (0.6-0.24 g/kg/day). Accounting for dif-
ferent body surface areas of mice and adult men with a correction fac-
tor of 0.08,152 the equivalent humanDHAdoses to replicate these pre-
clinical studies would range from 0.048 to 0.19 g/kg of DHA per day.
Thiswould be equivalent to providing 3.36 to 13.3 g ofDHAper day for
a 70 kg individual (Table 2). These large doses of triglyceride-DHA for-
mulas are unrealistic for human consumption and implicate the need
to develop alternative DHA formulations that can escape catabolism.
The effects of DHA supplementation on behavioral and biochemi-
cal measures were demonstrated in rodent models carrying amyloid
mutations153–155 orAPOE ɛ4 allele knock-inmodels156,157 using higher
doses and long-termDHA supplementation to diet.
In humans, DHA is consumed primarily fromoily fish, whereas other
sources include liver and eggs. DHA supplements are commonly pro-
vided in the form of an algal-derived triacylglycerol (TG) form or in
pure DHA ethyl esters (Table 1). From a pharmacological perspective,
absorption of DHA is similar between TG and ethyl esters of DHA
formulations.158 Although DHA supplements penetrate into the brain,
there are very fewDHAdosing studies guiding the informationonDHA
penetration to the brain. In the omegaAD trial, 1720 mg of DHA (in
ethyl esters) per day over 6 months was associated with only an 11%
increase in CSF DHA levels, as opposed to a two-fold (200%) increase
in plasma DHA levels.159 In the ADCS-sponsored DHA trial, 2 g of
DHA daily (Algal TG derived), a 38% increase in CSF DHA levels was
observed as opposed to a 207% increase in plasma DHA levels.160 In
the DHA Brain Delivery Pilot trial that recruited cognitively normal
older adults, 2 g DHA daily (Algal TG derived), led to a 28% increase
in CSF DHA levels.161 Therefore, DHA doses of less than 2 g per day
may lead to relatively small [<20%] increases in CSF or brain DHA lev-
els. This may provide an explanation whereby clinical trials using 1 g or
lower doses of omega-3 were negative for cognitive outcomes.162
Furthermore, because the majority of ingested DHA is transported
esterified to lipids, the half-life of DHA depends on the turnover of its
carrier molecule. the half-life of DHA is ≈3 weeks in plasma phospho-
lipids and 4 months in red blood cell membranes.163 In contrast, the
half-life of DHA in tissue compartments is much slower. In the brain,
Umhau et al. demonstrated using 11C DHA positron emission tomog-
raphy (PET) scans that DHA half-life is ≈2.5 years.164 Even within
the brain, different compartments may have different DHA turnover
rates, with synaptic DHA turnover occurring at faster rate165,166 than
other brain tissues. Similar to the brain, the half-life of polyunsaturated
fatty acids in adipose tissues is around 3 years.167 The slower turnover
of DHA in the brain implies that a modest reduction in DHA intake
or increase in DHA consumption may take several years to remodel
brain DHA within neuronal membranes. Unless there is severe DHA
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TABLE 2 Comparison of omega-3 study designs between human and animal trials
Human trials using omega-3
supplementation Animal studies using a DHA dietary intervention
Dose 0.003-0.03 g/kg/day 0.6-0.24 g/kg/day
Age at the onset of intervention >65 years 3-4months
Duration of intervention 4weeks to 5 years 12weeks to 8months
Effects on Cognition Null Enhanced cognitive functions
Effects on Aβ/Tau No change in CSF Aβ/tau160 Decrease tau and Aβ
Effects on synaptic functions Not directly studied Enhanced expression of synaptic proteins
Abbreviation: Aβ, amyloid beta.
depletion or deficiency secondary to strict dietary restriction or a
metabolic defect, short-term DHA supplementation will less likely
affect brain DHA levels.
Delivery of DHA to the brain may be enhanced using phospho-
lipid DHA esters instead of TG DHA esters. Phospholipid DHA for-
mulations have a longer plasma half-life,168 and associate with HDL
metabolism. In addition, the incorporation of DHA into the sn-1 posi-
tion of dietary phospholipids can enhance its brain bioavailability169 by
limiting aphospholipaseA2–mediated lossofDHAduring its peripheral
circulation. Another strategy to enhance brain DHA delivery focuses
on enhancing brain apoE lipidation. APOE lipidation is dependent on
ABCA-1activity.170 DHAwhenadded to themediumof glial cells in cul-
ture is incorporated into membrane phospholipids, and then secreted
as the fatty acid moiety of phospholipids mostly to APOE-containing
lipoproteins.171 APOE-containingDHAexhibits a strong effect on neu-
rite outgrowth of hippocampal neurons by increasing the number of
branches.171 Therefore, enhancing brain APOE lipidation represents
a mechanism to mobilize DHA from glial stores into APOE lipopro-
teins and, therefore, facilitate its brain transport in tissueswith greater
APOE receptor expression such as the hippocampus.
7.3.2 Omega-3 fatty acid intake and the response
to supplementation
An association has been shown between serum DHA and brain amy-
loid accumulation in persons at risk of dementia.149 However, this asso-
ciation was driven largely by persons at the lowest quartile of serum
DHA levels, that is, thosewho do not consumemuch seafood. TheMul-
tidomain Alzheimer Preventive Trial (MAPT) was designed to assess
the effects of DHA (800 mg) and EPA (to a maximum of 225 mg), mul-
tidomain intervention in cognitive function in frail subjects with mem-
ory complaints older than 70 years of age. In the main analysis of
MAPT, no significant effects of the interventions were found on cogni-
tion after adjustment for multiple testing. Exploratory sub-group anal-
ysis showed that participants on n-3 PUFA supplementationwith a low
omega-3 index (DHA + EPA ≤4.83%, representing the lowest quartile
of omega-3 index distribution) at baseline showed a trend toward less
cognitive decline over 36months in comparison to subjects on placebo
with low baseline omega-3 index.172 PREVENTE4 (NCT03613844) is
testing whether high dose (2 g/day) algal-derived DHA supplementa-
tion over 2 years would benefit non-demented older individuals with
low baseline omega-3 intake andwho are at increased risk of dementia
based on APOE genotype and cardiovascular risk factors.
7.4 Omega-3 fatty acids: Summary and
recommendations
In summary, epidemiology studies might support a protective effect
of increasing PUFA consumption when supplementation starts early
and lasts for a considerable amount of time to allow n-3 to remodel
within brain cells. Moreover, high dose and long-term DHA supple-
mentation amelioratesADpathology in rodentmodels. Short-termand
low-dose omega-3 supplements are unlikely to produce meaningful
effects sizes on cognitive outcomeswith ongoing clinical trials, as these
often include individuals with already-sufficient omega-3 blood levels
or significant evidence of neurodegeneration, in which case reversing
the pathology may not be possible. Furthermore, there are the com-
plexities and confounding associated with dietary patterns and change
in dietary patterns overtime in different populations.
1. Recommendations: Omega-3 clinical trials should begin with a
focus on appropriate exposure level and sample selection, with clin-
ical outcomes associated with lower PUFA intake and levels and
responsive to supplementation and careful measure of confound-
ing. Selection of participants at increased risk of dementia, for
example, cognitively normal APOE ε carriers, may increase the like-
lihood of success.
2. Either greater doses of current TG-DHA formulations or better
brain-penetrant formulations may need to be tested over longer
time frames and in those without significant evidence of neurode-
generation.
8 HOMOCYSTEINE AND B VITAMINS
Epidemiological studies have established that raised plasma total
homocysteine (tHcy)—a marker of B vitamin status—and low-normal
blood levels of the B vitamins folate, B6, and B12 are risk factors for
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dementia, including AD.173–177 Plausible mechanisms for this associ-
ation have been described174,175,178,179; these include mediation by
damage to the cerebral vasculature and the formation of phosphory-
lated tau, leading to brain atrophy.
Several meta-analyses have estimated the population attributable
risk (PAR) of dementia for raised tHcy. On the assumption that raised
tHcy has a prevalence of some30% in the elderly population, estimates
of PAR range from12% to 31% in four of themeta-analyses, with a fifth
estimating that the PAR is 4.3%.176 Thus a substantial proportion of
dementia may be caused by elevated tHcy.
In view of the high PAR, it is important that raised tHcy can readily
be lowered by the oral administration of three B vitamins (folate, B6,
and B12). The doses of these vitamins that are required to lower tHcy
are considerably larger than can readily be obtained from the diet. A
limited number of trials have been carried out with these high doses
in people with dementia, MCI, or normal elderly but with conflicting
results. Some of the reasons for these conflicting results have been dis-
cussed. 174–176
Here, we make recommendations specifying the conditions that
should be fulfilled in any trial of homocysteine-lowering B vitamins in
relation to cognition, based upon Table 2 in176
Appropriate sample selection is needed:
1. Elevated tHcy or suboptimal B vitamin status should be present
in the participants so that benefit can occur. No benefit could be
expected if the participants already have an adequateBvitamin sta-
tus. Hence, it is crucial to measure tHcy or B vitamins at baseline. It
is noteworthy that some trials have not done this (eg, Ref 180, 181).
2. Study participants in the trial should be at risk of cognitive decline
or already showing decline, but should not have a diagnosis of
dementia. In patients with dementia it is likely, as is applicable for
most interventions, that the degenerative process has proceeded
too far for any clinicallymeaningful modification of the disease pro-
cess to be possible. It was found, for example, in the ADCS trial141
that patientswithmoderately severe dementia did not benefit from
homocysteine-lowering treatment but those with mild dementia
did show some benefit.
Appropriate outcomesmust bemeasured:
1. The outcome measured must be sufficiently sensitive to change
over the duration of the trial. Screening tests likeMMSE have often
been used in trials but these are rarely sufficiently sensitive to
detect a meaningful change over a short time. More specific cog-
nitive tests should be used and in addition, or alternatively, sensi-
tive objective and physical measurements such as the rate of brain
atrophy determined by magnetic resonance imaging (MRI)182 can
be used.
2. The duration of the trial should be long enough tomeasure clinically
relevant change, such as cognitive decline, in the placebo group.
This period should be at least 12 months and preferably 2 years, in
particular if conversion to dementia is being assessed. It is notewor-
thy thatmany trials do not fulfill the criterion of cognitive decline in
F IGURE 2 Directed acyclic graph analysis of B vitamin treatment
and consequential changes in brain structure and function inmild
cognitive impairment (MCI). Themediating pathway shows the
optimal Bayesian network that explains the findings from the
VITACOG trial
Abbreviations: CDR, Clinical Dementia Rating scale; MMSE,
Mini-mental state examination; tHcy, total homocysteine.
the placebo group: for example, in a New Zealand trial, the placebo
group had an MMSE score of 29.17 ± 0.16 at baseline and 29.32 ±
1.10 after 2 years; therewas no effect of B vitamin treatment.183 In
the meta-analysis by Clarke,184 76% of 20,431 participants in the
trials did not have baseline measures of cognition, and so it was not
possible to determine cognitive decline in the placebo group; this
fact must cast doubt on the validity of the authors’ conclusions.
The dose should be adequate:
1. The doses of the vitamins should be sufficient to lower tHcy in
the majority of the participants, which means that food-based vita-
mins will not be adequate. Doses needed are typically: folate 0.4 to
0.8 mg, B6 10 to 20 mg, and B12 0.5 mg, and these can be taken
orally.
Analyses should take appropriate account of subgroups, confound-
ing, and interaction:
1. It is crucial that the analyses pre-specified in the trial protocol
include subgroup analysis in relation to baseline levels of tHcy
and/or of the B vitamins. It may be that the beneficial effect will be
the greater, the higher the baseline tHcy.
2. The protocol should specify analyses adjusted, or stratified, accord-
ing to other factors known to influence cognitive decline, such as





















































































































Target population (age) .  
The epidemiological evidence is generally most robu st for risk factor exposure at a 
particular time in the life -course , e.g. ,  midlife. However , most clinical trials have taken 
place in populations at different ages, e.g. , late-life. 
 X   X    X     X  
P opulation subgroups to consider .  
Different subgroups may respond differently to risk reduction (e.g. ,  there may be 
differences between those with and without a genetic risk profile ). T hese may need to 
be selected for in trial populations . 
 X   X   X   X X  X  X 
Level of baseline risk factor /level of severity .  
Risk factor levels may differ in clinical trial and epidemiological samples .  E.g. , 
population samples will likely include  people with a greater range of  severity than a 
selective clinical trial population.  
 X   X   X   X X  X  
Dementia type, balance of pathology/severity.  
Population samples are likely to show a range of dementia severity and patholog y 
whereas interventions may need to be targeted to a specific at risk group.   
 X   X    X   X   X  
Type of treatment/drug class/specific drug.  
Some drugs may have direct effects on cognition and therefore be more effective  
than others. Trials are usually selective in their choice of treatment whereas 
observational studies will have a range of treatment types.  
 X   X   X   X  X   X  
Combined treatments .  
C ombined treatments changing multiple risk factors may be required to achieve 
benefit. Trials are likely to have focused on individual treatments.  
     X   X  
Dose of intervention . 
Trials usually select a restricted range of doses which may miss the therapeutic level 
needed for cognition. Epidemiological studies are more likely to have a range of 
doses but often do not report details of doses.  
 X   X   X    X   X  
Expected goal level/size of the change in risk factor required.  
To select an at risk population and test the efficacy of risk reduction in a trial 
population we need more evidence to understand  the risk factor  levels  that are 
associated with the best cognitive outcomes.  
 X   X   X    X    
Duration of intervention /length of clinical trials .  
Treatment is usually required long -term, whereas trials run for a few years at most.          X   X   X   X   X   X   X  
 
 X  
No discrepancy identified or no evidence available  
F IGURE 3 Common areas of discrepancy identified by expert review for each of the seven risk factors
age and APOE genotype, and to factors like omega-3 fatty acids and
antiplatelet drugs that appear to interact specifically with B vita-
mins (see subsequent text).
Relatively few published trials of B vitamins in relation to cog-
nition have satisfied all the above criteria. These include the FACIT
trial of folic acid over 3 years140; the VITACOG trial of folic acid, B6,
and B12 in MCI over 2 years, reviewed in Smith175; and two trials
in MCI from China on folic acid for 2 years185 and on folic acid and
B12 for 6 months.186 All of these trials reported a beneficial effect
of the B vitamin treatment on cognitive or clinical function. Many
trials that were deficient in one or more of the above criteria have
been reported as negative, but in fact such conclusions cannot be
drawn.
The VITACOG trial not only assessed cognitive and clinical mea-
sures but also measured total and regional brain atrophy. In the
intention-to-treat analysis, the B vitamin treatment in 180 partici-
pants who had volunteered for MRI scans slowed whole brain atro-
phy by 30% overall, but in participants with tHcy in the top quar-
tile (>13 μmol/L) the B vitamin treatment slowed brain atrophy by
53%.182 The slowing of brain atrophy by B vitamin treatment was not
influenced by the APOE ɛ4 allele status. Regional brain atrophy, in par-
ticular in the medial temporal lobe, was markedly slowed, by almost
90%.187
Subsequent analysis showed that the beneficial effects of theB vita-
minswere restricted to participantswhohad a goodomega-3 fatty acid
status as well as elevated tHcy.188,189 Confirmation of this interaction
has come from a trial showing that a combination of folic acid andDHA
treatment was more effective in improving cognition in patients with
MCI than either nutrient alone.190 A theoretical basis for this inter-
action between two classes of nutrients has been proposed.175,191,192
Evidence that this interaction operates in the opposite direction as
well, that is, good B vitamin status (low tHcy) facilitates the cogni-
tive improvement after administering omega-3 fatty acids, has been
provided.193
The VITACOG trial has drawn attention to several factors that can
influence the response to treatment with B vitamins, such as the base-
line level of tHcy, the possible influence of omega-3 fatty acids, and the
useof aspirin byparticipants. For aspirin, itwas found that thosepartic-
ipants who regularly took aspirin, but not those taking other NSAIDS,
showed no slowing of brain atrophy after B vitamin treatment.182 Sim-
ilarly, aspirin use appeared to interfere with the beneficial cognitive
effects of B vitamins in MCI (T. Kwok et al., unpublished data). These
factors, and possibly the use of other drugs such as lipid-lowering
16 of 23 PETERS ET AL.
TABLE 3 Themismatch between the epidemiological and clinical trial evidence: Challenges and opportunities
Challenges Opportunities
Target population in terms of ageThe
epidemiological evidence is generally
strongest for risk factor exposure inmidlife;
however, themajority of the clinical trials
have taken place in later-life populations
with a short duration of follow-up.
Unrealistic to develop clinical trials that
modify risk and protective factors during
mid-life and examine its effects on late-life
dementia. Therefore, the trial efficacy is
often examined under a hypothesis (or
assumption) that given the
treatment/intervention could be provided
at later age, it would still show efficacy.
Important to examine differential efficacy
levels across different age groups to
develop sensitive outcomemeasures for
the reliable detection of changes.
Additional opportunities could includemore
sophisticated use of epidemiological data to
understand risk factor variation and
interactions over time/life-course, causal
analyses of observational data,196 or the
selection of future clinical trial participants
with fully characterized past histories.
Target population in terms of characteristics
of the participants
There is a lack of data on the potential for
different levels of benefit in different
sub-groups, eg, risk factor level/severity or
co-occurrence, a genetic risk or variations
in the balance of different contributory
dementia pathologies.
Themore subgroups we include, the smaller
sample size for each subgroup, thereby
lowing the statistical power
Harmonized diagnosis of dementia sub-types
are often lacking in epidemiological studies.
Risk factor levels/severity and clusteringmay
differ in clinical trial participants and
epidemiological cohorts.
Careful selection of trial populations.Additional
epidemiological work (new studies or
further precise reporting from existing
data) may be required to understand the
risk factor/outcome relationship across
cohorts with different risk scores, chronic
conditions, lifestyle factors, and baseline
disease severity and pathologies.
Target intervention.Type and dose of
intervention drug or combination of drugs
We have not yet identified the levels of each
risk factor that are associatedwith the best
outcomes for cognition nor whether this
differs by prior exposure.
Additional epidemiological work to identify
potential targets for change
(goals/biomarker change, etc.)
supplemented by a greater understanding
of the physiological processes and their
potential inter-connectivity alongside trials
looking at different goals or treatment
targets.
drugs, should always be taken into account when trials of B vitamins
are designed.
It has been concluded that the VITACOG trial has already fulfilled
the criteria for diseasemodification inMCI,194 with the causal pathway
shown in Figure 2. Trials of a combination of B vitamins and omega-3
fatty acids are now needed in people who have elevated tHcy, to see
if this simple and safe treatment can slow, or prevent, the conversion
fromMCI to dementia.
9 DISCUSSION
Although dementia risk reduction has never been more important, the
evidence so far, at least for the risk factorsweexamined, is not yet suffi-
cient to drive clear guidelines, although some pointers have been iden-
tified. In particular, there are common areas of discrepancy between
the observational and clinical trial evidence across the seven risk fac-
tors.
Experts in the relevant field appraised each of the seven risk fac-
tors independently, and yet when we pool all of these appraisals we
find a series of commonalities. These are shown in Figure 3 and can
be summarized as those affecting population selection (age, subgroups,
key characteristics, dementia type/pathology), those relating to the risk
factor (level of baseline severity, relative importance of change in risk
factor level), and those relevant to treatment (drug type/class, dosage,
duration of treatment, need for combination treatment).
9.1 Limitations
We have chosen seven established risk factors that are all modifiable
with pharmacological intervention, althoughwe acknowledge that risk
factor interaction or clustering is possible and single interventions are
not necessarily reflective of real life. There are also risk factors where
pharmacological intervention is not possible and/orwhere blinded clin-
ical trials are not feasible, and they too are likely to face some of the
issues we have identified; examples might include air pollution, alco-
hol, or social engagement. Related to this is the potential for com-
monalities among the mechanistic pathways. For example, a potential
role for vascular and inflammatory etiologies is evident, with vascu-
lar pathways most strongly but not exclusively linked to diabetes,13
cholesterol,52 BP,66,68,69 and homocysteine,174,175,178,179 and inflam-
matory pathways to estrogen195 and omega-3 fatty acids,145 although
this may not be the whole story with hyperglycemia15 and BP66,70–72
hypothesized to increase amyloid deposition and genetic alterations in
cholesterol trafficking directly related to risk ofAD.50 Furthermore the
work on NSAIDs reminds us to be “vigilant to potential sources of bias,
not least thoseof reverse causality andconfoundingby indication.” Fur-
ther limitations come from the inherent differences between obser-
vational studies and clinical trials, where the former is able to accrue
long follow-up but unlikely to modify the risk factor exposure or treat-
ment. The latter bydesignhas an interventionand is likely tobe shorter.
Finally, to take the first steps in moving the field forward, we have cho-
sen to focus on the similarities between the different risk factor and
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treatment pairs rather than the differences. However, these are also a
potential source of insight. For example, age at exposure seems more
pertinent to some risk factors than others. Although a full evaluation of
the differences is beyond the scope of this article, we recommend that
they tooare exploredwith a view toward informing thenext generation
of research on dementia risk reduction.
Our use of expert appraisal could be considered as both a limita-
tion and a strength. We did not seek to carry out a systematic review,
as there are multiple systematic reviews already published for each
of these seven risk factors. Instead, we have brought together expert
perspectives in a consensus and critical commentary of the current
evidence. In turn this has highlighted the different directions that the
epidemiology and clinical trial evidence has taken across the different
risk factors; for example, the availability of epidemiological evidence
for some risk factors is heavily based around the risk factor exposure
and outcome (eg, BP), whereas for others, the evidence is greater for
the association between the treatment and the outcome (eg, HT). Alto-
gether, this underscores the importance of a critical lens when inter-
preting the existing evidence and a need for a more in-depth under-
standing going forward.
Overall, we synthesize the challenges and opportunities (Table 3)
faced across the risk factors, and we argue that the design of new
observational studies and, in particular, new clinical trials, should be
both informed by the issues we raise and supported by careful analy-
ses and understanding of the existing data eg, using techniques such as
causal inference).196
We argue that to gain a greater understanding of the remain-
ing areas of uncertainty and the issues associated with these is
a requirement. Before planning future trials and when building a
robust justification for future trials, both targeted and method-
ologically sophisticated investigations are needed. Such evaluations
might include re-examining past trials and observational data along-
side a pragmatic approach, remaining alert to the possibility that
interventions may not modify the risk of dementia. In this context,
overall, for NSAIDs the dementia risk reduction story seems close
to complete. The current clinical trial evidence arguably holds the
most promise for anti-hypertensive use and supplementation by B
vitamins, but even for these and other interventions, more work
is needed to fully evaluate impact and reduce bias, not the least
in greater understanding of the appropriate trial populations and
interventions.
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